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Abstract
Aims: To develop a representative, self‐report assessment of lower urinary tract
symptoms (LUTS) for men and women, the symptoms of Lower Urinary Tract
Dysfunction Research Network Symptom Index‐29 (LURN SI‐29).
Methods: Women and men seeking treatment for LUTS at one of six academic
medical centers in the US were assessed at baseline, 3‐month and 12‐month
intervals. Twelve‐month data on 78 LURN SI‐29 items were analyzed among 353
women and 420 men using exploratory factor analysis (EFA), with factor structure
confirmed using confirmatory factor analysis (CFA). Internal consistency,
reliability, and validity of the five developed scales were evaluated by assessing
correlations with the American Urological Association Symptom Index (AUA‐SI),
the genitourinary pain index (GUPI), and the Pelvic Floor Distress Inventory‐20
(PFDI‐20), and by examining expected sex differences in scores.
Results: EFA results (n = 150 women; 150 men) produced an interpretable
eight‐factor solution, with three of the factors comprised of dichotomous items
addressing LUTS‐associated sensations. The remaining five factors, confirmed
with CFA in an independent sample of 473 participants, produced five scales:
incontinence, urgency, voiding difficulty, bladder pain, and nocturia. Subscales
For a copy of the LURN SI-29, contact the corresponding author
(d-cella@northwestern.edu).
and total LURN SI‐29 scores were correlated as expected with AUA‐SI, GUPI,
and PFDI‐20. LURN SI‐29 scores also performed as expected in differentiating
men from women based upon clinically expected differences, with men
reporting more voiding difficulties and nocturia, and women reporting more
urgency and incontinence.
Conclusions: The LURN SI‐29 questionnaire has the potential to improve
research and clinical outcome measurement for both men and women with LUTS.
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1 | INTRODUCTION
Lower urinary tract symptoms (LUTS), common among
adult men and women,1,2 can adversely affect sleep, mood,
daily functioning, and work productivity.3-5 In 2012, the
National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK) established the symptoms of Lower
Urinary Tract Dysfunction Research Network (LURN),
with six tertiary care clinical research sites and a data
coordinating center. The charge was to identify and explain
the important subtypes of LUTS and improve the measure-
ment of patient experiences of LUTS.6
While there are a number of validated patient‐
reported measures of LUTS available to clinicians and
researchers, no instrument captures the full spectrum of
LUTS with interpretable scales that can be used for
outcome measurement. For example, the LUTS tool,
which captures severity and bother for a comprehensive
range of symptoms, provides no scoring system nor
information on important differences, making measure-
ment of change over time challenging. The American
Urological Association Symptom Index (AUA‐SI) was
initially developed for men with benign prostatic
hyperplasia, provides scoring and interpretation informa-
tion, but it does not contain questions regarding urinary
incontinence (UI). Most other instruments focus on a
particular symptom complex such as overactive bladder
or UI but do not assess the spectrum of LUTS.
To address this gap, LURN investigators developed a
Comprehensive Assessment of Self‐Reported Urinary
Symptoms (CASUS),7 which assesses a comprehensive set
of 93 manifestations of LUTS. The goal of the current
research was to reduce this comprehensive set of questions
to a representative set of items for use as a clinical or
research outcome questionnaire that captures aspects of
LUTS relevant to both sexes.7 To develop this clinically
relevant questionnaire, we used factor analyses as well as
input from our large group of expert clinicians to ensure
that the outcome questionnaire was psychometrically
strong and included content appropriate for patients.
2 | MATERIALS AND METHODS
2.1 | Study design
Data were obtained from the LURN Observational
Cohort Study.8 Treatment‐seeking men and women were
recruited between June 2015 and January 2017 and
completed in‐person clinic visits at baseline, 3 and 12
months. At baseline, participants completed a physical
examination and questionnaires related to LUTS and
other symptoms. Questionnaires were repeated at 3 and
12 months. As LURN CASUS was developed while the
Observational Cohort Study was underway, only a subset
of participants was administered the full questionnaire at
baseline (n = 64, women and n = 212, men). However,
most were administered LURN CASUS at 12 months.
This analysis was performed using LURN CASUS
responses from 12‐month questionnaires, and thus
included all participants that had sufficiently complete
12‐month LURN CASUS forms (defined as at least 85% of
the form completed).
2.2 | Exploratory factor analyses
Candidate subscales were identified using exploratory
factor analyses (EFAs) based on a random sample of 300
participants (150 women and 150 men). Sex‐specific
questions, questions that were suppressed by the survey
branching logic, and questions with a very low frequency
of endorsement were excluded from the analyses, leaving
78 of 93 possible questions available for EFA. Because the
response options included dichotomous and polytomous
items, we performed multiple EFAs, specifying different
factor solutions, using polychoric correlations to estimate
correlations between the underlying continuous vari-
ables. Oblique rotation accounted for the known correla-
tions between factors. For each factor identified, loadings
from the individual items were provided as standardized
regression coefficients (unlike correlation coefficients,
standardized regression coefficients can occasionally
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exceed 1.0). Scree plots and parallel analysis were used to
guide the selection of the number of useful factors.
Solutions ranging from 4 to 10 factors were reviewed by
eight members of the study team, and the final solution
was chosen by consensus, based on the interpretability.
Factor loadings greater than 0.4 were required for
inclusion of an item in a designated factor. After the
most interpretable factor solution was derived, the
internal consistency reliability of each scale was assessed
using Cronbach's alpha.
2.3 | Scale development
Once the optimal number of factors was chosen, each
factor was reviewed by the study team (two urologists,
two urogynecologists, one statistician, and three out-
comes researchers) who nominated the most clinically
relevant items from among those with loadings above 0.4.
This process resulted in excluding three factors due to
poor interpretability. All remaining factors were reviewed
with relevant data, including item content and internal
consistency of various item combinations, and the group
reached consensus on the final scale composition of the
questionnaire. This 29‐item questionnaire is referred to
as the LURN Symptom Index‐29 (LURN SI‐29).
2.4 | Confirmatory factor analysis
LURN SI‐29 response data from a second unique sample
of 471 participants (203 women; 268 men) with 12‐month
data were analyzed to assess the consistency of factor
loadings with the EFA results and to evaluate the fit of
the response data to the factor solution selected from the
EFA process. Confirmatory factor analysis (CFA) was
conducted separately for men and women. The fit was
assessed using root mean squared error of approximation
(RMSEA), comparative fit index (CFI), and the non‐
normed fit index (NNFI).
2.5 | Scaling and initial validation
After establishing interpretable subscales of the LURN SI‐
29, summed raw scores were transformed to 0‐100 scale
using linear transformations of each subscale raw sum. A
total LURN SI‐29 score was computed as the simple raw
sum of all responses, also transformed to a 0‐100 scale.
2.6 | Associations between LURN SI‐29
scales and validated measures of urinary
symptoms
Validity testing for the LURN SI‐29 scores was performed
in the LURN study population with complete 12‐month
LURN SI‐29 questionnaires. Initial validation of the
LURN SI‐29 was performed by studying its associations
with concurrently administrated questionnaires that
capture a wide range of symptoms experienced in people
with LUTS, including the AUA‐SI,9 the genitourinary
pain index (GUPI),10 the pelvic floor distress inventory
(PFDI‐20) (administered in women only),11 and a UI
severity score calculated from the LUTS tool.12 Multi-
variable linear regression was used to test for associations
between the LURN SI‐29 scales and the relevant
subscales of AUA‐SI, GUPI, UI severity score from the
LUTS tool, and the PFDI‐20 (women only). Models were
run separately for men and women and both standar-
dized and unstandardized regression coefficients were
reported. All analyses were conducted using SAS version
9.4 (SAS Institute, Cary, NC).
3 | RESULTS
3.1 | Demographic characteristics
Table 1 provides demographic and clinical information
for the EFA and CFA samples. Participants in both
cohorts were on average 60 years old, mostly non‐
Hispanic whites, and held an associate's degree or higher.
The EFA sample was selected to be 50% female, whereas
the CFA sample, unselected for sex, including 43%
women. Most participants had AUA‐SI scores in the
moderate range.
3.2 | EFA and scaling
From the 78 candidate items, the eight‐factor solution
provided the most interpretable result (Table S1):
incontinence (16 items), pain (16 items), voiding
difficulties (12 items), urgency and bother (9 items),
nighttime symptoms (3 items), sensations when needing
to urinate (4 items), sensations between urinations
(8 items), and sensations “that could not be put into
words” (2 items). The last three (sensation) factors
reflected the LURN effort to characterize, with dichot-
omous (yes/no) questions, the sensory variability of
LUTS for possible diagnostic or phenotyping purposes;
as such they were excluded from consideration for the
LURN SI‐29.
On the basis of consensus, a 6‐item incontinence scale
was selected (Table S2), including items on leaking at
night, completely losing bladder control, leaking with
feelings of urgency, leaking when laughing, sneezing, or
coughing, and leaking with physical activity. Median
scores (0‐100 range) were 8.3 in women and 0 in men,
respectively, with an interquartile range of 0‐20.8
(women) and 0‐0 (men) and a score range of 0‐100 in
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women and 0‐45.8 in men (Figure 1A). The very low
scores among men is consistent with previous descrip-
tions of this study population.8
The 4‐item bladder pain factor queries the nature,
frequency, and intensity of pain and discomfort at
different points in the bladder filling and emptying
process. The study team review preferred frequency—
over intensity‐type questions; therefore the final bladder
pain scale included items related to the frequency of pain
and discomfort while the bladder was filling, when it was
full, during urination, and right after urination (Table
S2). The median rescaled score of this scale was 6.25
(interquartile range [IQR] = 0‐12.5) in both men and
women with no participant scoring the maximum
possible score of 100 (maximum observed score = 75.0
in women and 81.3 in men, Figure 1B).
After the study team presented two options for the
voiding difficulty scale, the LURN Steering Commit-
tee approved an alternative 5‐item version (Table S2).
It consists of items related to straining, hesitancy,
intermittency, weak stream, and postvoid dribble. The
median score for the voiding difficulty scale was
higher in men than women (25 [IQR = 10‐40] vs
10 [IQR = 5‐20]) with scores varying across the full
range of the scale in men but not in women
(maximum score = 83.3; Figure 1C).
The 3‐item urgency scale (Table S2) assesses how
often respondents felt a sudden need to urinate, difficulty
in delaying urination, and fear of leaking urine due to a
sudden need to rush to urinate. The median score was
33.3 (IQR= 16.7‐50.0) in women and 25 (IQR= 8.33‐
33.3) in men with scores across the full range of the scale
(Figure 1D). A correlated “bother” item was retained by
the Steering Committee for clinical relevance but not
scaled with urgency.
A 3‐item Nocturia scale (Cronbach's alpha = 0.76)
originally included the nighttime leakage question;
however, the LURN Steering Committee felt it was more
clinically appropriate in the incontinence scale and also
removed the item related to nighttime urgency from the
scale. Thus, the final Nocturia scale (Table S2) included
items related to the number of nighttime voids and
frequency of waking up due to a need to void. Scores
were higher in men compared with women (median
score = 71.4 [IQR= 42.9‐85.7] vs 57.1 [IQR= 28.6‐71.4];
Figure 1E).
Table S3 reports inter‐subscale correlations. Most of
the correlations are below 0.40, indicating that each
subscale is measuring a unique symptom domain. The
only correlation that consistently exceeded 0.40 was that
between urgency and incontinence. Urgency and pain
were correlated 0.42 in women but did not exceed 0.40 in
men or overall.
TABLE 1 Demographics and baseline data on participants with
12‐mo LURN SI‐29 completed
EFA sample
(n = 300)
CFA sample
(n = 473)
Age mean (SD) 59.3 (13.5) 59.7 (13.4)
Sex n (%)
Male 150 (50%) 270 (57%)
Female 150 (50%) 203 (43%)
Race n (%)
African American 33 (11%) 58 (12%)
Other 25 (8%) 40 (9%)
White 241 (81%) 373 (79%)
Ethnicity n (%)
Hispanic/Latino 17 (6%) 14 (3%)
Non‐Hispanic/non‐
Latino
277 (92%) 448 (95%)
Ethnicity unknown 6 (2%) 11 (2%)
Education n (%)
<High school/GED 5 (2%) 11 (2%)
HS diploma/GED 24 (8%) 39 (8%)
Some college 61 (21%) 105 (23%)
Associate's degree 25 (9%) 36 (8%)
Bachelor's degree 87 (30%) 125 (27%)
Graduate degree 91 (31%) 146 (32%)
Employment status n (%)
Used part‐time 40 (13%) 49 (11%)
Used full‐time 115 (39%) 179 (38%)
Unemployed 9 (3%) 16 (3%)
Not used 133 (45%) 222 (48%)
Marital status n (%)
Married/civil union 193 (65%) 317 (68%)
Living with partner 6 (2%) 17 (4%)
Separated/divorced 46 (15%) 51 (11%)
Widowed 17 (6%) 15 (3%)
Single 37 (12%) 68 (15%)
BMI (median, IQR) 28.9 (25.7‐32.9) 28.6 (25.1‐33.1)
Current tobacco user n (%) 24 (8%) 26 (5%)
Diabetes n (%) 46 (15%) 73 (15%)
Functional comorbidity
index (median, IQR)
2.0 (1.0‐4.0) 2.0 (1.0‐3.0)
PVR (median, IQR), mL 29.5 (10.0‐80.0) 24.0 (0.0‐65.0)
AUA‐SI (median, IQR) 13.0 (8.0‐18.0) 12.0 (8.0‐17.0)
AUA QOL (median, IQR) 4.0 (3.0‐5.0) 4.0 (3.0‐5.0)
Abbreviations: AUA‐SI, American Urological Association Symptom
Index; BMI, body mass index; CFA, confirmatory factor analysis; EFA,
exploratory factor analysis; GED, general educational diploma; IQR,
interquartile range; LURN SI‐29, Lower Urinary Tract Dysfunction
Research Network Symptom Index‐29; PVR, postvoid residual; QoL,
quality of life.
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3.3 | Confirmatory factor analysis
CFA showed that, as with the EFA, all factor loadings
remained above 0.4 when examining a second
independent dataset. Inspection of fit indices for the
five‐factor solution indicated a good fit based on
RMSEA (Table S4). CFI and NNFI, however, ranged
from 0.813 to 0.891, suggesting that the data deviate
from the hypothesized model, perhaps due to some
content diversity in the correlated items comprising
the scales.
3.4 | Additional LURN SI‐29 items
The LURN Steering Committee proposed a set of
remaining questions, not associated with any of the
five factors, to be included on the outcome measure
separately from the scales. This list comprised nine
items that were deemed clinically relevant: frequency
of daily voiding, nighttime urgency, constant urgency,
feeling of incomplete emptying, leakage just after
voiding, sex‐specific questions related to splitting,
spraying, or change of direction of urine stream, and
overall bother. These questions were not scaled,
however, they were included in a total LURN SI‐29
score obtained by summing all 29 questions and
rescaling from 0 to 100.
3.5 | Sex differences
Figure 1 provides LURN SI‐29 subscale scores separately
by sex, indicating that whereas men and women report
similar pain scores, women report more urgency and
incontinence, and men report more voiding difficulty and
nocturia. Overall, it appears that the average total LUTS
burden is comparable for men and women (LURN SI‐29
total median score = 21.5 for women, 21.7 for men, see
Figure 1F), but the variability of scores was significantly
greater for women than for men (variance 156.62 vs
86.00, P< .001).
3.6 | Initial validation
Table 2 demonstrates associations between LURN SI‐29
scores and concurrently administered questionnaires.
Multivariable models regressing the AUA‐SI on the
LURN SI‐29 scales showed associations between the
AUA‐SI and all subscales in women and all subscales
except incontinence in men (Table 2). The GUPI was
similarly associated with all subscales in men and all
subscales except nocturia in women. For men and
women, the UI severity score from the LUTS tool was
associated with the incontinence, voiding difficulty, and
urgency scales, but not the bladder pain or nocturia
scales. In women, the PFDI‐20 was associated with all
FIGURE 1 LURN SI‐29 Scales by sex (n = 353, females and 420, males). Large circles are male means and small circles are male outliers
(ie, greater than 1.5 times the interquartile range). Large pluses are female means, and small pluses are female outliers. The line in the box
indicates the median, and the lower and upper edges of the box represent the 25th and 75th percentiles, respectively. The whiskers extend to
1.5 times the interquartile range (ie, the distance between the 25th and 75th percentiles). LURN SI‐29, Lower Urinary Tract Dysfunction
Research Network Symptom Index‐29
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LURN SI‐29 scales except nocturia. All associations were
positive, that is, higher (more severe) scores on the LURN
SI‐29 scales were associated with higher (more severe)
scores on the validated scales. When the distribution of
the LURN SI‐29 scales was considered by AUA‐SI
severity category (mild [1‐7], moderate [8‐19], and severe
[20‐35]), all scales showed an increasing trend by severity
category (Figure 2), with the exception of incontinence in
men, which is not measured by AUA‐SI.
4 | DISCUSSION
The goal of this research was to create an outcome
measure for clinical research to quantify symptom
severity across various types of LUTS. Empirically, we
found that items grouped together in a clinically mean-
ingful way, and factor loadings from EFA were replicated
in an independent CFA sample. Across the total sample,
all of the scales had sufficient internal consistency. Some
of the CFA fit indices suggested a mismatch between the
observed data and the various factor models. This is most
likely due to the unique information captured by certain
items within subscales (eg, for bladder pain, there are
questions about pain during urination vs pain between
voids). EFA and CFA served as useful guides to scale
construction in this study; candidate items selected from
EFA were then selected based on clinical relevance, with
a specific eye toward avoiding repetition when selecting
from among the items loading >0.4 on the respective
factor. This may have had an adverse effect on the CFA
fit statistics. Nevertheless, the internal consistencies of all
scales remained above 0.7 in an independent sample.
Thus, it may be helpful for clinicians to consider each
item independently when assessing patients, in addition
to minding summary scores. The converting of each scale
to a 0‐100 metric can enable easy comparing across scales
and can aid in clinical interpretation.13
Not surprisingly, comparing men and women on
responses to the LURN SI‐29, women reported more
urgency and incontinence, whereas men reported more
voiding difficulty and nocturia. There were no sex
differences in pain, nor were there differences by sex in
the LURN SI‐29 Total. Subscales of the LURN SI‐29 were
associated with relevant scales from the LUTS tool, AUA‐
FIGURE 2 LURN SI‐29 scales by sex and LUTS severity as measured by AUA‐SI severity categories (n = 335, females and 399, males).
AUA‐SI scores missing for n = 18 females and n = 21 males. AUA‐SI, American Urological Association Symptom Index; LUTS, lower
urinary tract symptoms
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SI, GUPI, and PFDI‐20. These high associations with a
diverse set of questionnaires offer hope that the LURN SI‐
29 might have value across different populations,
including men and women. Broadly, the data provide
support for the LURN SI‐29 as a potential outcome tool,
so future studies should investigate its feasibility as an
endpoint in clinical trials, as well as determine clinically
meaningful differences between distinct patient groups,
and within patient groups over time.
Strengths of our research include the multicenter
study population of treatment‐seeking patients with
LUTS and our multidisciplinary (including input from
clinicians, social scientists, and psychometricians) and a
rigorous approach to measure development and testing.
We also acknowledge the limitations. Our sample was
not ethnically diverse and was also highly educated, and
although our multicenter research enhances general-
izability to other treatment‐seeking populations, we have
not tested the LURN SI‐29 in nontreatment‐seeking
people with LUTS. LURN SI‐29 use should be limited
to patient populations pending further testing. Finally,
data were not available to calculate test‐retest reliability.
This will be important to establish in future research.
5 | CONCLUSIONS
In summary, the LURN SI‐29 is a new 29‐item patient‐
reported outcome tool. It was developed from a longer,
comprehensive set of urinary symptom items developed
by the LURN for use in phenotyping research.7 Five brief
scales measuring urgency, incontinence, voiding diffi-
culty, nocturia, and pain are supplemented with nine
individual questions measuring voiding, nighttime ur-
gency, constant urgency, incomplete emptying, leakage
just after voiding, splitting, spraying, or change of
direction of urine stream, and overall bother, together
producing a total score. Internal consistency coefficients
of the scales were consistently above the acceptable
threshold of 0.70, and the scales were correlated with
other commonly used LUTS questionnaires. Further
validation and use in LUTS outcomes research is
encouraged.
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